Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation
NCT00148980 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2011-04-28
Summary
Normal bone marrow function depends on the coexistence of normal hematopoietic stem cells and a microenvironment mostly located in the medullary part of the bones. Stem cells cannot function properly in the absence of an adequate microenvironment. Whereas in malignant and non-malignant hematologic diseases caused by a deficiency or abnormal stem cells, stem cell transplantation is the treatment of choice that results in a cure, in diseases such as MDS, myelofibrosis, and other conditions associated with an abnormal microenvironment, pancytopenia may occur despite the presence of apparently normal hematopoietic cells with no recognizable cytogenetic abnormality.
We, the investigators at Hadassah Medical Organization, proved in experimental studies that the entire osteohematopoietic complex consisting of trabecular bone, hematopoietic microenvironment (of stromal origin) and hematopoietic tissue has been successfully transferred directly into ablated bone marrow cavity in a one-step transplantation procedure.
The goal of this study is to enhance hematopoiesis in patients with myelofibrosis syndrome by intraosseous inoculation of demineralized bone matrix (DBM) together with allogeneic bone marrow cells (BMC).
Conditions
Interventions
- DEVICE
-
DBM for creation of bone marrow microenvironment
Sponsors & Collaborators
-
Hadassah Medical Organization
lead OTHER
Principal Investigators
-
Olga Gurevitch, PhD · Hadassah Medical Organization
Study Design
- Allocation
- NON_RANDOMIZED
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-04-30
Countries
- Israel
Study Locations
More Related Trials
-
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
NCT02167958 ·Status: COMPLETED ·Phase: PHASE1
-
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
NCT01350258 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
NCT00008307 ·Status: UNKNOWN ·Phase: PHASE2
-
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
NCT00047268 ·Status: UNKNOWN ·Phase: PHASE3
-
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
NCT00113828 ·Status: TERMINATED ·Phase: PHASE2
-
Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
NCT00489281 ·Status: TERMINATED ·Phase: PHASE2
-
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
NCT02724904 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
NCT01067287 ·Status: COMPLETED ·Phase: PHASE2
-
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
NCT00104975 ·Status: COMPLETED ·Phase: PHASE1
-
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
NCT00636909 ·Status: COMPLETED ·Phase: PHASE2
-
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft
NCT00814983 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00044954 ·Status: COMPLETED ·Phase: PHASE2
-
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
NCT00003196 ·Status: COMPLETED ·Phase: NA
-
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
NCT00134004 ·Status: COMPLETED ·Phase: PHASE2
-
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
NCT02653196 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Bone Marrow Transplantation in Treating Children With Sickle Cell Disease
NCT00004485 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation
NCT01252784 ·Status: UNKNOWN
-
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
NCT00113646 ·Status: TERMINATED ·Phase: PHASE2
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
NCT03970096 ·Status: RECRUITING ·Phase: PHASE2
-
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
NCT00544466 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Stem Cell Transplantation for Children Affected With Osteopetrosis
NCT00145587 ·Status: TERMINATED ·Phase: NA
-
Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes
NCT01674985 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer
NCT00002809 ·Status: COMPLETED ·Phase: PHASE2
-
Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia
NCT00001144 ·Status: COMPLETED ·Phase: PHASE2